Note 1 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)
Number of Tumor Samples	150,000
Number of Operating Segments	3
Retained Earnings (Accumulated Deficit)	$ 171,980,726		$ 167,761,883
Cash and Cash Equivalents, at Carrying Value	5,197,235		8,728,660
Liabilities, Current	4,516,661		3,951,031
Operating Lease, Liability, Noncurrent	2,027,348		$ 2,188,979
Net Cash Provided by (Used in) Operating Activities	$ 3,416,021	$ 3,427,761